Assessing the disease-liability of mutations in CFTR

Claude Ferec, Garry R. Cutting

Research output: Contribution to journalArticle

Abstract

Over 1900 mutations have been reported in the cystic fibrosis transmembrane conductance regulator (CFTR), the gene defective in patients with cystic fibrosis. These mutations have been discovered primarily in individuals who have features consistent with the diagnosis of CF. In some cases, it has been recognized that the mutations are not causative of cystic fibrosis but are responsible for disorders with features similar to CF, and these conditions have been termed CFTR-related disorders or CFTR-RD. There are also mutations in CFTR that do not contribute to any known disease state. Distinguishing CFTR mutations according to their penetrance for an abnormal phenotype is important for clinical management, structure/function analysis of CFTR, and understanding the molecular and cellular mechanisms underlying CF.

Original languageEnglish (US)
Article numbera009480
JournalCold Spring Harbor Perspectives in Medicine
Volume2
Issue number12
DOIs
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Assessing the disease-liability of mutations in CFTR'. Together they form a unique fingerprint.

  • Cite this